請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76745
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴逸儒(I-Rue Lai) | |
dc.contributor.author | Chi-Ju Wu | en |
dc.contributor.author | 吳季儒 | zh_TW |
dc.date.accessioned | 2021-07-10T21:36:08Z | - |
dc.date.available | 2021-07-10T21:36:08Z | - |
dc.date.copyright | 2020-09-10 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-18 | |
dc.identifier.citation | 1. 國民健康署106年癌症登記報告:https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269 pid=12235. 2. Lyons, K., et al., Gastric cancer: epidemiology, biology, and prevention: a mini review. Eur J Cancer Prev, 2019. 28(5): p. 397-412. 3. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424. 4. Machlowska, J., et al., Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci, 2020. 21(11). 5. Lauren, P., The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand, 1965. 64: p. 31-49. 6. Zheng, H., et al., Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol, 2007. 60(3): p. 273-7. 7. Cancer Genome Atlas Research, N., Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014. 513(7517): p. 202-9. 8. Rice TW, K.D., Blackstone EH, et al. Esophagus and esophagogastric junction. In: Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer Staging Manual, 8th ed. New York: Springer, 2017:185-202. 9. Son, T., et al., Multi-institutional validation of the 8th AJCC TNM staging system for gastric cancer: Analysis of survival data from high-volume Eastern centers and the SEER database. J Surg Oncol, 2019. 120(4): p. 676-684. 10. Robbe, C., et al., Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J, 2004. 384(Pt 2): p. 307-16. 11. Dhanisha, S.S., et al., Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit Rev Oncol Hematol, 2018. 122: p. 98-122. 12. Senapati, S., S. Das, and S.K. Batra, Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci, 2010. 35(4): p. 236-45. 13. Kaur, S., et al., Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol, 2013. 10(10): p. 607-20. 14. Jonckheere, N. and I. Van Seuningen, The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie, 2010. 92(1): p. 1-11. 15. Banos-Lara Mdel, R., B. Piao, and A. Guerrero-Plata, Differential mucin expression by respiratory syncytial virus and human metapneumovirus infection in human epithelial cells. Mediators Inflamm, 2015. 2015: p. 347292. 16. Rachagani, S., et al., Current status of mucins in the diagnosis and therapy of cancer. Biofactors, 2009. 35(6): p. 509-27. 17. Moniaux, N., et al., Structural organization and classification of the human mucin genes. Front Biosci, 2001. 6: p. D1192-206. 18. Kufe, D.W., Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer, 2009. 9(12): p. 874-85. 19. Chauhan, S.C., et al., Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol, 2006. 19(10): p. 1386-94. 20. Schroeder, J.A., et al., MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene, 2004. 23(34): p. 5739-47. 21. Shimamura, T., et al., Overexpression of MUC13 is associated with intestinal-type gastric cancer. Cancer Sci, 2005. 96(5): p. 265-73. 22. van Putten, J.P.M. and K. Strijbis, Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer. J Innate Immun, 2017. 9(3): p. 281-299. 23. Udhayakumar, G., et al., Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer. Mol Carcinog, 2007. 46(9): p. 807-17. 24. Allen, A. and A. Garner, Mucus and bicarbonate secretion in the stomach and their possible role in mucosal protection. Gut, 1980. 21(3): p. 249-62. 25. Senapati, S., et al., The MUC gene family: their role in the diagnosis and prognosis of gastric cancer. Histol Histopathol, 2008. 23(12): p. 1541-52. 26. Nordman, H., et al., Human gastric mucins--a major population identified as MUC5. Biochem Soc Trans, 1995. 23(4): p. 533S. 27. Reis, C.A., et al., Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer, 1998. 79(4): p. 402-10. 28. De Bolos, C., M. Garrido, and F.X. Real, MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach. Gastroenterology, 1995. 109(3): p. 723-34. 29. Ho, S.B., et al., Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res, 1995. 55(12): p. 2681-90. 30. Zhang, C.T., et al., Prognostic value of Muc5AC in gastric cancer: A meta-analysis. World J Gastroenterol, 2015. 21(36): p. 10453-60. 31. Ohno, T., et al., Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer. Eur J Cancer, 2006. 42(2): p. 256-63. 32. Higuchi, T., et al., MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met. Mol Cell Biol, 2004. 24(17): p. 7456-68. 33. Xiao, X., et al., Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer. J Transl Med, 2013. 11: p. 151. 34. Zheng, F., H. Yu, and J. Lu, High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer. J Cell Biochem, 2019. 35. Chen, C.H., et al., MUC20 promotes aggressive phenotypes of epithelial ovarian cancer cells via activation of the integrin beta1 pathway. Gynecol Oncol, 2016. 140(1): p. 131-7. 36. Chen, S.T., et al., Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene, 2018. 37(46): p. 6041-6053. 37. Wang, Q., et al., Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol, 2012. 29(1): p. 77-83. 38. Deng, N., et al., A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut, 2012. 61(5): p. 673-84. 39. Liu, S.Y., et al., Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation. Oncotarget, 2016. 7(10): p. 11251-62. 40. Hu, W.T., et al., The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities. Am J Cancer Res, 2018. 8(9): p. 1739-1751. 41. Yasui, W., et al., Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. Pathol Int, 1999. 49(9): p. 763-74. 42. Tahara, E., Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol, 1993. 119(5): p. 265-72. 43. Fenoglio-Preiser, C.M., et al., TP53 and gastric carcinoma: a review. Hum Mutat, 2003. 21(3): p. 258-70. 44. Yasui, W., et al., Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res, 1999. 90(6): p. 589-95. 45. Wang, D., et al., High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival. Oncol Lett, 2017. 13(5): p. 3003-3013. 46. Inokuchi, M., et al., Clinical significance of MET in gastric cancer. World J Gastrointest Oncol, 2015. 7(11): p. 317-27. 47. Alsina, M., et al., Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. Ann Oncol, 2015. 26(2): p. 438-9. 48. Choi, R.S., et al., Current and future molecular diagnostics of gastric cancer. Expert Rev Mol Diagn, 2019. 19(10): p. 863-874. 49. Matsubara, J., et al., Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res, 2008. 14(10): p. 3022-9. 50. Oda, K., et al., A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol, 2005. 1: p. 2005 0010. 51. Birchmeier, C. and W. Birchmeier, Molecular aspects of mesenchymal-epithelial interactions. Annu Rev Cell Biol, 1993. 9: p. 511-40. 52. Danilenko, D.M., et al., Neu differentiation factor upregulates epidermal migration and integrin expression in excisional wounds. J Clin Invest, 1995. 95(2): p. 842-51. 53. Pinkas-Kramarski, R., et al., Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J, 1996. 15(10): p. 2452-67. 54. Yarden, Y. and M.X. Sliwkowski, Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001. 2(2): p. 127-37. 55. Yarden, Y. and G. Pines, The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer, 2012. 12(8): p. 553-63. 56. Pochampalli, M.R., R.M. el Bejjani, and J.A. Schroeder, MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene, 2007. 26(12): p. 1693-701. 57. Workman, H.C., C. Sweeney, and K.L. Carraway, 3rd, The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res, 2009. 69(7): p. 2845-52. 58. Li, Y., et al., The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem, 2001. 276(38): p. 35239-42. 59. Li, Y., et al., The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem, 2001. 276(9): p. 6061-4. 60. Schroeder, J.A., et al., Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem, 2001. 276(16): p. 13057-64. 61. Higuchi, T., et al., Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem, 2004. 279(3): p. 1968-79. 62. Weichert, W., et al., Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer, 2004. 90(4): p. 815-21. 63. Guo, H., et al., Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis, 2011. 32(12): p. 1897-904. 64. https://www.rndsystems.com/products/proteome-profiler-human-phospho-rtk-array-kit_ary001b#product-datasheets. 65. Chen, C.H., et al., MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer. Gynecol Oncol, 2013. 128(3): p. 560-7. 66. Tiemin, P., et al., MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. J Hepatol, 2020. 72(4): p. 761-773. 67. Huang, Y. and Y. Chang. Epidermal Growth Factor Receptor (EGFR) Phosphorylation, Signaling and Trafficking in Prostate Cancer. 2011. 68. Kataoka, Y., et al., HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer, 2013. 16(1): p. 84-93. 69. Kufe, D.W., MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013. 32(9): p. 1073-81. 70. Ahmad, R., et al., MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal, 2011. 4(160): p. ra9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76745 | - |
dc.description.abstract | 背景: 胃癌是台灣十大常見癌症之一,即使透過外科手術、化學藥物等方式來治療,胃癌病患在治療之後的五年存活率卻只有20-25%,而如此低的存活率主要與腫瘤的生長速度以及癌細胞的轉移有關。過去研究發現黏蛋白(mucin, MUC)可以當作訊息接受器或者透過細胞膜上的受體鉻胺酸激酶 (receptor tyrosine kinases, RTK)來調控細胞內的訊息傳遞並且藉此影響癌細胞的惡性程度。例如,腫瘤組織若表現大量MUC1的大腸直腸癌病患,其預後較差。研究也發現,MUC20的表現和子宮內膜癌、大腸直腸癌及胰臟癌等惡性程度皆有關係。然而,MUC20的表現和功能是否與胃癌惡性程度相關?目前還尚未得知。 目的: 探討MUC20是否會影響胃癌的惡性程度以及調控胃癌轉移的機制。 實驗材料與方法: 以免疫組織化學染色(immunohistochemical staining)及西方墨點法(western blot)探討胃癌病患的胃腫瘤組織檢體中MUC20的表現和臨床病理參數的相關性。以腸型胃腺癌細胞株AGS探討MUC20 過度表達對於細胞增生能力(crystal violet staining)、爬行能力(transwell migration assay)、侵襲能力(transwell invasion assay)的影響。並且使用人類受體鉻胺酸激酶晶片與西方墨點法分析MUC20過度表達是否會影響胃癌細胞株AGS中受體鉻胺酸激酶 (receptor tyrosine kinases, RTKs)及其下游蛋白的活化。 結果: 根據21個腸型胃腺癌檢體的西方墨點法分析結果,有較多(15/21個)病患其MUC20在胃腫瘤組織中的表現量相較於非腫瘤部分的黏膜組織高。根據71個病患腸型胃腺癌檢體的免疫組織化學染色結果,當胃腫瘤組織中MUC20表現較高(score>7)的時候,其癌細胞分化較差的比率(11/26 v.s 6/37)以及且發生遠端轉移(7/26 v.s 1/37)的機會均較MUC20表現低的那組病患高。在細胞實驗, MUC20過度表達的AGS細胞株會有較強的爬行能力及侵襲能力。相較於控制組(mock)細胞株,過度表達MUC20的胃癌細胞株其上皮生長因子接受器(Epidermal growth factor receptor, EGFR)的磷酸化程度較高,且EGFR的下游訊息傳遞與轉錄激活酶3(Signal transducer and activator of transcription3, STAT3)也會被活化。 結論: 腸型胃腺癌組織比非腫瘤部分的黏膜組織表現出較高MUC20。表現出高MUC20的胃癌病患,有較高機會出現遠處器官轉移且其癌細胞分化較差。從細胞實驗發現, MUC20過度表達的胃癌細胞株具有較強的爬行能力以及侵襲能力,這個表現型可能和MUC20活化EGFR路徑的機制有關。 | zh_TW |
dc.description.abstract | Background: Gastric cancer (GC) is one of the ten most common cancers in Taiwan. Even though some of the GC patients were cured by surgical resection and/or chemotherapy, the overall 5-year survival rate of GC was only twenty to twenty-five percent, mostly due to the uncontrolled cancer growth and metastasis. Previous studies reported that mucin glycoproteins could function as receptors or bind to receptor tyrosine kinases (RTKs) to regulate signal transduction and cancer progression. For instance, the colorectal cancer patients with mucin 1 (MUC1) overexpression had poorer prognosis than those without. Several studies also demonstrated that mucin 20 (MUC20) was associated with endometrial, colorectal and pancreatic adenocarcinoma. However, the expression level and function of MUC20 in GC is still unclear. Aims: To investigate whether MUC20 could affect gastric cancer progression and the regulatory mechanism of MUC20 in gastric cancer. Materials and methods: Western blot analysis was performed to study the expression of MUC20 in the tumorous and non-tumorous tissue of the intestinal type gastric adenocarcinomas. Immunohistochemical staining was used to analyzed the correlation of the MUC20 expression in the cancerous part with clinico-pathological parameters of patients with the intestinal type gastric adenocarcinomas. AGS cells were transfected with MUC20/pcDNA3.1A vector to overexpress MUC20. Cell viability, migration, and invasion were analyzed by crystal violet staining, transwell migration and matrigel invasion assays, respectively. Human phospho-receptor tyrosine kinase array and western blot analysis were used to investigate the effects of MUC20 overexpression on RTK signaling in AGS cells. Results: Fifteen of the twenty-one samples assessed by western blot analysis showed MUC20 overexpression in the cancerous part of intestinal type gastric adenocarcinoma, when compared to the the non-tumorous mucosa tissue. The immunohistochemical staining of 71 gastric cancer tissue samples showed that higher percentage of poor cell differentiation (11/26 v.s 6/37) and distant metastasis (7/26 v.s 1/37) in MUC20 high expression (scores>7) group than MUC20 low expression (scores<6) group. In vitro studies showed that overexpression of MUC20 in AGS cells enhanced their abilities to migrate and invade. Moreover, MUC20 overexpression increased phosphorylation of epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) in AGS cells. Conclusions: Our findings suggested that MUC20 was overexpressed in the intestinal type gastric adenocarcinoma tissue compared with the non-tumorous mucosa tissue. The patients with MUC20 high expression had higher chances of distant metastasis, and their cancer cells often were classified as poorly-differentiated. Our in vitro studies suggested that MUC20 may increase gastric cancer cell migration and invasion through EGFR pathway. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T21:36:08Z (GMT). No. of bitstreams: 1 U0001-1808202017110200.pdf: 4571350 bytes, checksum: b5120f45581dd1521d5c06a6f99db92d (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書 i 致謝 ii 摘要 iii Abstract v 第一章 緒論 1 1.1前言 1 1.2胃癌組織分類及臨床病理期別 1 1.3黏液與黏蛋白(mucin, MUC)簡介 2 1.3.1黏蛋白如何影響癌症的進展 4 1.3.2黏蛋白在胃中的表現 5 1.3.3黏蛋白20 (MUC20)影響癌症進展的研究 5 1.3.4黏蛋白20 (MUC20) 在胃癌中的表現 6 1.4調控胃癌進展的分子 6 1.4.1上皮生長因子接受器 (Epidermal growth factor receptor, EGFR) 7 1.5研究目的與實驗設計 8 第二章 實驗材料以及方法 9 2.1 細胞株之培養 9 2.2 病患檢體、臨床資料與MUC20陽性控制組切片 9 2.3 西方墨點法 (Western blot analysis) 10 2.3.1蛋白質萃取 10 2.3.2蛋白質濃度測定 10 2.3.3蛋白質樣品製備 11 2.3.4電泳膠片製作 11 2.3.5 蛋白質電泳實驗 12 2.3.6 蛋白質轉印 12 2.3.7 蛋白質抗體染色 12 2.4 免疫組織化學染色 (Immunohistochemical staining) 13 2.4.1石蠟切片 13 2.4.2石蠟切片脫蠟 14 2.4.3 抗原修復 (Antigen retrieval) 14 2.4.4 染色 14 2.4.5 切片脫水以及封片 15 2.5免疫組織化學染色評分 (IHC evaluation) 15 2.6細胞增生實驗 (Crystal violet staining ) 16 2.7細胞爬行實驗 (Transwell migration assay) 16 2.8細胞侵襲實驗 (Transwell invasion assay) 17 2.9人類磷酸化受體酪氨酸激酶晶片(Human phospho-receptor tyrosine kinase array, R D Systems) 17 2.10數據統計分析 18 第三章 結果 19 3.1 MUC20在胃腺癌組織中的表現 19 3.2比較臨床檢體中MUC20表現與臨床參數之間的相關性 19 3.3 MUC20對於腸型胃腺癌細胞株AGS表現型態(phenotype)的影響 19 3.4 MUC20過度表達(MUC20 overexpression)增強上皮生長因子接受器(epidermal growth factor receptor, EGFR)與人類上皮生長因子第二型接受器(Human Epidermal Growth Factor Receptor 2, ErbB2)的磷酸化程度 20 3.5 探討MUC20是否會藉由透過上皮細胞生長因子接受器(EGFR)影響胃癌細胞株的表現型態 21 3.6 研究MUC20是否會磷酸化EGFR路徑下游的蛋白質 21 第四章 討論 23 4.1實驗結果與其他MUC20相關腫瘤研究的討論 23 4.2本篇研究尚待解決的問題及有待進行的實驗 24 4.2.1 MUC20與臨床相關性研究 24 4.2.2 探討MUC20是否藉由EGF-STAT3誘導胃癌細胞株AGS爬行或侵襲 25 4.2.3 在體內系統,過度表現MUC20的胃癌細胞是否較易轉移? 25 4.2.4 探討MUC20影響受體酪氨酸激酶磷酸化程度的實驗 26 4.2.5 探討MUC20是否會藉由ErbB2影響胃癌細胞的表現型態 26 4.2.6 探討MUC20、EGFR與STAT3三者之間的關係 27 第五章 圖片與表格 28 圖1. MUC20在胃腺癌組織中的表現 28 圖2. 利用免疫組織化學染色分析MUC20在胃腫瘤組織中的表現強度與陽性比率 29 圖3. MUC20 overexpression效力 30 圖4. MUC20對於胃癌細胞株AGS爬行能力的影響 31 圖5. MUC20對於胃癌細胞株AGS侵襲能力的影響 32 圖6. MUC20對於胃癌細胞株增生能力的影響 33 圖7. MUC20過度表達(MUC20 overexpression)增強胃癌細胞株AGS中EGFR與ErbB2的磷酸化程度 34 圖8. MUC20增強胃癌細胞株AGS中EGFR的磷酸化程度 36 圖9. MUC20透過EGFR路徑來增強胃癌細胞株AGS的爬行能力 38 圖10. MUC20透過EGFR路徑來增強胃癌細胞株AGS的侵襲能力 39 圖11. 研究在胃癌細胞株AGS中MUC20是否會磷酸化EGFR路徑下游的訊息傳遞蛋白質AKT, ERK及STAT3 40 圖12. 證實MUC20過度表達(MUC20 overexpression)的AGS細胞株中STAT3是EGFR下游的訊息傳遞蛋白 42 表一 44 附錄 45 參考資料 47 | |
dc.language.iso | zh-TW | |
dc.title | 第二十型黏蛋白在胃癌進展的角色
| zh_TW |
dc.title | The role of mucin 20 in the gastric cancer progression | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃韻如(Yun-Ju Huang),黃敏詮(Min-Chuan Huang) | |
dc.subject.keyword | 胃癌,黏蛋白,受體鉻胺酸激酶,上皮生長因子接受器,訊息傳遞與轉錄激活酶3, | zh_TW |
dc.subject.keyword | gastric cancer,mucin,receptor tyrosine kinases (RTKs),epidermal growth factor receptor (EGFR),signal transducer and activator of transcription 3 (STAT3), | en |
dc.relation.page | 56 | |
dc.identifier.doi | 10.6342/NTU202004002 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1808202017110200.pdf 目前未授權公開取用 | 4.46 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。